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Abstract
Background: Mounting evidence supports a key role for VIP as an anti-inflammatory agent and promoter of
immune tolerance. It suppresses TNF-a and other inflammatory cytokines and chemokines, upregulates anti-
inflammatory IL-10, and promotes immune tolerant cells called T regulatory (Treg) cells. VIP KO mice have recently
been demonstrated to have spontaneous airway and pulmonary perivascular inflammatory responses, as part of
asthma-like and pulmonary hypertension phenotypes, respectively. Both inflammatory responses are correctable
with VIP. Focusing on this model, we have now investigated the influence of VIP not only on inflammatory cells
but also on Treg cells.
Methods: Using flow cytometric analysis, we examined the relative preponderance of CD25+CD4+ cells and anti-
inflammatory Treg cells, in extracts of thymus and spleen from VIP KO mice (5 VIP KO; 5 VIP KO+ VIP; 10 wild-type).
This method allowed antibody-based flow cytometric identification of Treg cells using surface markers CD25 and
CD4, along with the: 1) intracellular activation marker FoxP3; and 2) Helios, which distinguishes cells of thymic
versus splenic derivation.
Conclusions: Deletion of the VIP gene results in: 1) CD25+CD4- cell accumulation in the thymus, which is
corrected by VIP treatment; 2) more Treg in thymus lacking Foxp3 expression, suggesting VIP is necessary for
immune tolerance; and, 3) a tendency towards deficiency of Treg cells in the spleen, which is normalized by VIP
treatment. Treg lacking Helios are induced by VIP intrasplenically rather than by migration from the thymus. These
results confirm the dual role of VIP as an anti-inflammatory and immune tolerance-promoting agent.
Introduction
Background
We hypothesized: 1) Vasoactive Intestinal Peptide (VIP)
may be regulating the development and proliferation of
regulatory T lymphocytes (Treg); and 2) VIP can effi-
ciently and quickly induce Treg. Because they promote
immune tolerance and are anti-allergic, Treg are impor-
tant. Current methods of allergy immunotherapy, for
tree pollen, for example, reduce seasonal symptoms and
medication usage and costs, but are not efficient to
induce Treg and require slow protocols, taking years to
reach maximal dosage. The underlying immune
mechanisms of VIP and Treg interactions are not
entirely known. Better understanding of the VIP-Treg
system may pave the way to use VIP as an adjunct or
replacement for allergy immunotherapy, a treatment for
allergic asthma.
A defect in current literature is that other investiga-
tors have studied in vitro immune responses to VIP but
lacked the in vivo VIP knockout mouse model. Knowing
that Treg are a critical cell type to engage in order to
induce tolerance in allergic individuals, and having the
availability of VIP knockout (VIP KO) mice–a sponta-
neous model of asthma (airway inflammation and airway
hyper-responsiveness not requiring allergic sensitiza-
tion)–we were uniquely positioned to validate the role
of VIP in Treg expression from central thymus and per-
ipheral spleen in the VIP KO mice, untreated and trea-
ted with exogenous VIP replacement.
We also studied VIP KO mice under conditions of
allergic challenge and discovered large dendritic cell
accumulation, suggesting an immature dendritic cell
phenotype.
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Vasoactive Intestinal Peptide (VIP) is a neuropeptide
with properties not only as a vasodilator and smooth
muscle relaxant, as originally discovered by Sami I. Said
and Victor Mutt [1], but also has potent anti-inflamma-
tory effects. VIP is present in a variety of cells, including
mast cells and lymphocytes. VIP induces the release of
the anti-inflammatory cytokine IL-10 and suppresses
TNF-a and pro-inflammatory cytokines IL-2, IL-4, IL-5,
IL-6, IL-12, IL-17, chemokines GRO/KC, and CCL5
[2-9]. In recent literature, VIP also improves immune
tolerance by increasing anti-inflammatory, immune-tol-
erant T regulatory (Treg) cells in spleen [10].
We showed earlier that mice lacking the gene for VIP
have spontaneous features of asthma, with airway
inflammation (peribronchiolar lymphocytes and eosino-
phils) and pro-inflammatory cytokine production in
bronchoalveolar lavage fluid–yielding IL-5 and IL-6 [11].
It is unnecessary to use allergic sensitization to induce
these asthmatic changes, making the VIP mouse model
a unique genetic asthma phenotype. When VIP KO
mice are treated with VIP, these aspects of inflammation
are attenuated. Another characteristic of VIP KO mice is
lymphocytic perivascular inflammation of pulmonary
arteries. VIP treatment attenuates these features [2].
One treatment of allergic asthma is allergy immunother-
apy to induce immune tolerance by increasing Treg to
allergens, which are antigens such as tree pollen. Speci-
fic injection immunotherapy with dilute doses of tree
pollen often entails a slow course of two and a half
years, making this an inefficient process.
Delgado et al. reported that VIP treatment of dendri-
tic cells renders them anti-inflammatory and tolero-
genic. These VIP-treated dendritic cells induce T cells
to produce anti-inflammatory cytokine IL-10, and these
T cells have low proliferative capacity, indicating
immune suppression or tolerance. They also found that
these VIP-treated dendritic cells, when stimulated with
lipopolysaccharide, are antigen-specific. In addition, a
slight increase in FoxP3 mRNA expression was found in
CD4+ T cells generated with tolerogenic dendritic cells.
FoxP3 is necessary for survival and function of regula-
tory T cells (Treg)–key cells in maintaining tolerance
[10,12]. The critical role of Treg in preventing autoim-
mune disease and maintaining immune tolerance is well
established [13,14]. Prasse found that inhaled VIP in sar-
coidosis patients led to bronchoalveolar lavage fluid
(BALF) Treg cell populations expressing FoxP3. This
was concurrent with significantly reduced production of
inflammatory cytokine TNF-a by cells isolated from
BALF [15].
The Helios transcription factor has recently been
described as a central thymic transcription factor in
regulatory T cells independent of FoxP3 [16]. The
immunoregulatory role of VIP-Helios interactions has
not been studied.
With the use of VIP KO mice we demonstrated that
VIP replacement attenuated the asthma phenotype but
had not yet delineated a VIP’s mechanism of action [2].
This model now offers the opportunity to sample Treg
from thymus and spleen and test the hypotheses that: 1)
VIP may be regulating the development and prolifera-
tion of Treg; and 2) VIP may be efficient and quick in
induction of Treg.
Materials and methods
VIP knockout (KO) mice, backcrossed to C57BL/6, were
prepared as described [17]. We bred the mice locally
and genotyped them to confirm the absence of the VIP
gene [17]. We mated homozygous KO males with
homozygous KO females or, if necessary, with heterozy-
gous KO females. For genotyping, we extracted DNA
from 1-cm-long tail snips using a DNA isolation kit
(Qiagen, Valencia, CA). DNA (100 ng) was subjected to
PCR using primers to detect both VIP and the neomycin
cassette. Control, wild-type (WT) C57BL/6 mice were
from Taconic Laboratories (Germantown, NY). All
experiments and animal care procedures were approved
by the Institutional Animal Care and Use Committee
and were conducted according to National Institutes of
Health Guide for the Care and Use of Laboratory
Animals.
Experiments were performed on 3 groups of mice (n =
5 in VIPKO and VIPKO+VIP groups; n = 10 in the
wild-type group): 1) 6-9 month-old C57BL/6 control
male mice; 2) age and gender-matched VIP KO mice
treated with buffer PBS; and 3) VIP KO mice treated
with VIP at 15 nmol i.p. every other day for 2 weeks (7
doses). VIP knockout mice have been described pre-
viously (reference). One day after the last dose of VIP or
buffer, the mice were anesthetized with pentobarbital 10
mg/kg, tracheotomized and 0.8 ml of blood were with-
drawn in a heparinized tube via cardiac puncture. The
spleen and thymus were removed and placed in a Falcon
tube with RPMI media and stored on ice until labeling
with antibodies for flow cytometric analysis of FOXP3
and Helios. The spleen and thymus were teased apart
and disaggregated on top of a cell strainer in a cell cul-
ture dish containing 5 ml of cold media (FACS wash).
The cell suspension was transferred to a 50 ml conical
tube, centrifuged 10 minutes, resuspended in 5 ml RBC
lysis buffer, and incubated for 3 minutes at room tem-
perature. The cells were then centrifuged and washed
twice with 15 ml FACS wash buffer, 350 × g 5 minutes
and resuspended at 5 × 106/ml.
The cells were labeled with 5 microliter One step
staining Mouse Treg Flow™ kit (FoxP3 Alexa Fluor®
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488/CD25PE/CD4 Per CP) with 100 μl of cell suspen-
sion l antibody for 20 minutes followed by fixing with
FoxP3 fix/perm buffer (Biolegend Cat. No. 421401) at
room temperature for 20 minutes. The cells were then
permeabilized in FoxP3 perm buffer (Biolegend Cat No.
421402,) for 20 minutes, labeled with FoxP3 for 20 min,
and washed twice with FoxP3 perm buffer. The cells
were then labeled with anti-Helios (22f6) (Biolegend
Cat. No. 137203 Alexa Fluor® 647) for 20 minutes at
room temperature, centrifuged, washed twice, resus-
pended, and analyzed by flow cytometry. Lymphocyte
and macrophage populations were defined by forward
and sideward scatter, according to cell granularity and
size [18]. 10,000 cells is the standard sample size in
most flow cytometric analyses, so 50,000 is sufficient for
our methods. We determined that 5 μl of antibody was
sufficient to stain cells at that concentration. We were
always staining in a small sample volume. Though this
is our exclusive method there is no need to increase the
sample size.
The results were expressed as the total number of
cells of the given cell phenotype being reported divided
by the total number of cells counted (to normalize
slightly different counts between tubes) multiplied by
100,000 (to work with whole numbers, since the percen-
tages were often small). The total cells analyzed in most
cases were greater than 50,000.
Statistical analysis
T-cell expression data (CD4, CD25, FoxP3, Helios) for
spleen and thymus cells of the three treatment groups
(controls, VIP KO, and VIP KO + VIP) were summar-
ized by descriptive statistics: medians, minimums, and
maximums. Three pair-wise comparisons were made
using non-parametric Mann-Whitney tests: controls vs.
VIP KO, controls vs. VIP KO + VIP, and VIP KO vs.
VIP KO + VIP. To adjust for multiple comparisons, a P-




Compared to WT mice, VIP KO mice had high num-
bers of cells expressing CD25, the IL-2 receptor a-
chain. These CD25+CD4- thymic cells are in the lym-
phocyte gate. Treatment of the VIP KO mice with VIP
suppressed these cells. In wild-type mice, the mean
number of Treg cells was higher than that in untreated
VIP KO mice, which showed a trend toward fewer Treg
cells with CD4+CD25+FoxP3+ in the spleen. Treatment
with VIP increased the number of Treg cells with FoxP3
+Helios+CD4+CD25+ in spleen. Treg were induced
intrasplenically in those cells CD4+CD25+FoxP3
+Helios- since Helios is found on 100% of thymic-
derived Treg and only 70% of splenic-derived Treg.9
Therefore, lack of Helios in these VIP-induced Treg iso-
lated from spleen indicates that they were generated
from VIP interactions in spleen rather than migrating
from the thymus. VIP KO mice also had more Treg
lacking expression of FoxP3, the critical survival factor
for Treg, compared to wild-type mice.
Increased CD25+CD4-Cells in Thymus in VIP KO Mice:
reduction with VIP treatment
In VIP KO mice, we identified CD25+ (IL-2 receptor
positive) cells which were CD4 negative. CD4-CD25
+Helios+ cells were markedly increased in the thymus of
VIP KO mice (2689 cells, range 2520-2966) compared
to control animals (3.0, range 0-22). They were reduced
with VIP treatment, supporting the concept of VIP as
an endogenous anti-inflammatory agent. VIP treatment
of VIP KO mice reduced CD4-CD25+Helios+ thymus
cell numbers to 1558 with a range between 450-1783
(Table 1).
Increased numbers of FoxP3-Treg in Thymus in VIP KO
Mice
VIP KO mice, compared to wild-type mice, had
increased mean numbers (141 vs. 46) of Treg cells lack-
ing FoxP3 expression (CD4+CD25+FoxP3-Helios+).
Increased Treg with VIP therapy in thymus of VIP KO
mice
To determine if absence of VIP leads to suppression of
regulatory T cells, we quantified Treg in thymus and
spleen from control and VIP KO mice. In the thymus,
VIP KO mice had Tregs (CD4+CD25+) levels similar to
control mice, (204 cells; range 177-281, vs. 159; range
56-563), which were increased with VIP treatment, with
P = 0.0091 (Table 1). An example of a VIP KO mouse
treated with VIP leading to high numbers of thymic
Treg compared to an untreated VIP KO mouse is
shown in Figure 1. Also in Figure 2., VIP treatment ele-
vates Treg numbers at high levels even greater than
untreated wild-type.
Control and VIP KO spleen levels of Treg (triple-
staining CD4+CD25+FoxP3+) cells were statistically simi-
lar, yet showed a trend towards suppression in VIP KO
mice: 109, range 8-359 for the wild-type, and 9, range 4-
37 for VIP KO. Treatment with VIP increased these
Treg (triple-staining) cells in VIP KO mice. Treatment
with VIP in VIP KO mice increased triple-staining Treg
(CD4+CD25+FoxP3+) cell levels from 9.2 (range 4-37) in
untreated VIP KO to 150 (range 99-226) in VIP-treated
VIP KO mice; this was statistically significant (P =
0.0091). Quadruple-staining CD4+CD25+FoxP3+Helios+,
Treg cell numbers were similar in control (68 cells,
range 2-251) and VIP KO mice 6, range 0-22).
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Treatment with VIP in VIP KO mice resulted in
increased Treg (quadruple-staining CD4+CD25+FoxP3
+Helios+) cells (82; range 53-141), which was statistically
significant P = 0.0091.
With our small sample size, there was a trend, though
lack of statistical baseline suppression, in Treg in thy-
mus and spleen in VIP KO mice. It is, however, evident
that a statistically significant milieu exists with CD25
+CD4- cells, and that VIP not only is able to suppress
these CD25+CD4- cells, but also is simultaneously able
to increase Treg, expressing triple and quadruple-stain-
ing CD4+CD25+FoxP3+ and CD4+CD25+FoxP3+Helios+
cells.
Tables 1 and 2 summarize spleen and thymus data
among the three groups: 1) control; 2) VIP KO; and 3)
VIP KO+VIP. Centrally, in the thymus of VIP KO mice,
Table 1 Comparisons of T-cell expression in thymus cells among three mice groups
Group 1: Controls
(n = 10)
Group 2: VIP KO
(n = 5)
Group 3: VIP KO + VIP
(n = 5)
p-values for Group Comparisons
Median Min, Max Median Min, Max Median Min, Max 1 vs. 2 1 vs. 3 2 vs. 3
CD4-CD25+ 1146 666, 1831 3298 2953, 3517 3182 2579, 4109 0.0022* 0.0022* 0.47
CD4-CD25+Helios+ 308 110, 436 2690 2520, 2966 1558 450, 1783 0.0022* 0.0022* 0.0091*
CD4-CD25+FoxP3+Helios+ 3 0, 22 11 2, 15 43 21, 1771 0.18 0.0031* 0.0091*
CD4+CD25+
(Treg)
159 56, 563 204 177, 281 432 377, 596 0.63 0.015* 0.0091*
CD4+CD25+FoxP3+Helios-
(Treg induced intrasplenically)
44 0, 493 25 15, 58 48 25, 493 0.81 0.63 0.12
CD4+CD25+FoxP3-Helios+
(Treg)
46 4, 79 141 111, 166 141 23, 171 0.0022* 0.028 0.92
CD4+CD25+FoxP3+Helios+
(Treg)
21 0, 423 25 15, 53 31 16, 378 0.81 0.40 0.26



































Figure 1 VIP Facilitates Thymic Production Of Treg (Helios+Foxp3+CD4+CD25+). In this VIP KO mouse thymus treated with VIP, there were
596.09 Tregs expressing CD4 and CD25. This is in contrast to untreated VIP KO mice (fig. 3) which is associated with fewer Treg. Gated on CD4-
CD25+ lymphocytes (which were orange cellsin the figure above, there are more Helios+CD25+FoxP3+CD4- cells in VIP-treated VIP KO mice
than seen in untreated VIP KOmice shown in Fig.2 (red circle with arrow).
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CD25+CD4- cell numbers were high–3297 cells (median)
with a range from 2952 to 3517–whereas control
C57BL/6 mice numbers were lower: 1145 (range 665-
1830), supporting a pro-inflammatory milieu in the
absence of the VIP gene (P = 0.0022). When untreated
VIP KO mice thymus CD25+CD4-Helios+ cells were
compared to VIP-treated VIP KO, the levels (2689,
range 2519-2966) were suppressed to 1558 (range 450-
1783), P = 0.0091.
Treg Induced peripherally in spleen in VIP KO Mice
treated with VIP
Peripherally, in spleen, untreated VIP KO mice numbers
of Treg (CD4+CD25+FoxP3+) cells were 9.2 (range 3.6-
R3
Treg in WT 
mice 
(CD4+CD25+) 
in this slide 
greater than 

















WT mice have fewer NK 
or suppressor cells than 
VIP KO mice.
Thymic cells 
in WT mice 
are activated 
with FOXP3.
Figure 2 Wild-Type Thymus Associated With Lower Treg Numbers Than VIP-Treated VIP KO MiceA control mouse had intermediate
levels of CD4+CD25+ thymic Tregs (384.14) compared to VIPKO (177.07) and VIP-treated VIP KO (596.09). This supports the concept that VIP
can increase Treg centrally in thymus. Wild-type mice have fewer CD25+ cells compared VIP KO, suggesting that VIP is critical for suppression of
CD25+ cell expression.
Table 2 Comparisons of T-cell expression in spleen cells among three mice groups
Group 1: Controls
(n = 10)
Group 2: VIP KO
(n = 5)




Median Min, Max Median Min, Max Median Min, Max 1 vs. 2 1 vs. 3 2 vs. 3
CD4-CD25+ 29 6, 73 31 19, 429 47 33, 89 0.63 0.12 0.18
CD4-CD25+Helios+ 1 0, 4 4 0, 164 2 0, 10 0.046 0.31 0.61
CD4-CD25+FoxP3+Helios+ 4 0, 19 0 0, 0 0 0, 2 0.069 0.32 0.14
CD4+CD25+
(Treg)
435 88, 1383 374 199, 611 380 198, 489 1.00 1.00 0.61
CD4+CD25+FoxP3+Helios-
(Treg induced intrasplenically)
109 8, 359 9 4, 37 150 99, 226 0.038 0.91 0.0091*
CD4+CD25+FoxP3-Helios+
(Treg)
83 0, 270 254 108, 352 96 21, 157 0.028 0.91 0.029
CD4+CD25+ FoxP3+Helios+
(Treg)
68 2, 251 6 0, 22 82 53, 141 0.087 0.91 0.0091*
Note: p-values were based on Mann-Whitney tests; *: statistically significant at adjusted alpha = 0.017.
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36), whereas VIP-treated VIP KO mice increased levels
to 150.4 (range 98-226). P = 0.0091. Treg (Quadruple-
staining CD4+CD25+FoxP3+Helios+) cells were low in
untreated VIP KO mice (5, range 0-21), and the level
increased with VIP-therapy to 82 (range 52-140), P =
0.0091. These are peripherally-induced Treg in spleen
since they lack Helios which is found in 100% of thymic
Treg and only 70% of splenic Treg. Absence of Helios
in these samples obtained from spleen indicates intras-
plenic activation. An example of a VIP KO mouse with
low numbers of Treg is shown in Figure 3.
Discussion
This study demonstrates that VIP KO mice have sponta-
neous accumulation of CD25+CD4- cells in the central
thymus compartment compared to wild-type mice.
These levels decrease in VIP KO mice treated with VIP.
Treg lacking FoxP3 were more plentiful in VIP KO
mice compared to wild-type, supporting the concept
that VIP is critical for immune tolerance.
Likewise, we showed decreased Treg centrally in thy-
mus (CD25+CD4+Helios+ cells) and a trend towards
reduction in immune tolerant CD4+CD25+FoxP3+ Treg
cells in VIP KO mice. Pituitary Adenylate Cyclase Acti-
vating Peptide (PACAP), a peptide similar to VIP in
sequence and function, has recently been reported to
enhance production of Treg [19]. So, since our VIP KO
mice were not double knockouts for VIP along with
PACAP, it is plausible that PACAP is the reason for
residual Treg. Nevertheless, suggesting a more dominant
role of VIP versus PACAP, this trend towards decreased
Treg was present in VIP KO mice vs. wide variance
among wild-type mice, using the most conservative
statistical adjustments.
VIP treatment of VIP KO mice was, nonetheless, sta-
tistically significant in increasing Treg numbers (CD4
+CD25+FoxP3+Helios+) and suppressing a pro-inflamma-
tory cell phenotype (CD25+CD4-). We did not deter-
mine the origin of these CD4+CD25+FoxP3+Helios+
cells–i.e., from the thymus or originating intra-spleni-
cally. Statistically significant increases in thymus Treg
(CD4+CD25+) and spleen Treg (CD4+CD25+FoxP3+)
were seen in VIP-treated VIP KO mice compared to
untreated VIP KO mice, supporting the concept that
VIP treatment induces the generation of Treg. Indeed,
in other mouse models VIP induces the generation of
these Treg from the CD4+CD25- T cell compartment.
[20] Treg isolated from spleen have an intrasplenic ori-
gin since they lack Helios, suggesting that VIP acts per-
ipherally, directly on the spleen. This is a novel finding
not studied during the creation of the VIP KO mouse

























VIP KO mice have 
low Treg
VIP KO
Figure 3 Lack Of VIP In VIP KO Mice Associated With Trend Towards Low Tregs in spleen or thymus? (Heliosfoxp3+CD4+Cd25+). In an
untreated VIP KO mouse, thymus CD4+CD25+ cells were less plentiful (177.07) compared to the 596.09 seen in the VIP-treated VIP KO mouse
above. Gated on CD4-CD25+ lymphocytes, only 15 Helios+CD25+FoxP3+CD4- cells were detected.
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literature postulating therapeutic potential for immune
homeostasis in 2007.[17]
The goal of this paper was to explore the development
of T regulatory cells in VIP knockout mice, particularly in
the thymus and spleen, and support the concept that exo-
genous VIP is able to induce Tregs. Future studies we are
contemplating include: 1) treating VIP KO animals for 2
weeks (15 ng VIP qod for 7 doses), followed by a 1 month
hiatus and then analyzing treg populations in spleen in
thymus–to determine if there are long-term effects on
Treg with VIP treatment; 2) In vitro stimulation of Tregs
from VIP KO mice to show their Helios and FoxP3
expression by isolating naïve CD4+CD25- cells from thy-
mus and spleen and stimulating them for 5 days with
CD3/CD28 beads and TGF Beta and IL-2. Expression of
CD4, CD25, FoxP3 and Helios by FACS will subsequently
by determined–this will verify if absence of VIP in Tregs
affects expression of these markers.
Our data support those reported by Delgado et al. on
the emerging, mounting evidence of the essential role of
VIP in immune tolerance, with particular modulation of
Treg. Tolerance to antigen is essential to alleviating clin-
ical manifestations of allergic diseases such as allergic
rhinitis, allergic asthma, and stinging insect anaphylaxis.
Autoimmune diseases such as Systemic Lupus Erythe-
matosus (SLE) are the epitome of self versus non-self
disarray, and knowing that FoxP3+ Treg cells are
depleted during attacks and flares of lupus, supports the
concept of VIP’s potential as a drug for SLE and other
autoimmune diseases and disorders with vasculitis.
It is possible that the CD4-CD25+ cells are not
inflammatory lymphocytes since they could be CD8
+CD25+ effector cells. Future experiments will be direc-
ted at determining this phenotype. Although we showed
that VIP KO mice have Treg lacking FoxP3 (CD4+CD25
+FoxP3-), they may be activated effector cells; yet, the
absence of FoxP3 would suggest that they lack a critical
molecule necessary for Treg survival.
In summary, lack of VIP in mice leads to CD25+CD4-
cells; VIP treatment suppresses these cells and increases
Treg in spleen. These experiments support the dual role
of VIP as an anti-inflammatory agent and immune toler-
ance promoter.
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